AbbVie signed an option‑to‑license agreement with Zejing Biopharmaceutical for alveltamig (ZG006), a trispecific T‑cell engager targeting DLL3; AbbVie paid $100 million upfront and could pay an additional $60 million near‑term, with total deal value above $1.07 billion in milestones. Zejing retains Greater China rights while AbbVie holds global development and commercialization obligations. Alveltamig is in Phase I/II testing for DLL3‑expressing tumors including small cell lung cancer, and the deal follows FDA approval of a separate DLL3 T‑cell engager, underscoring commercial interest in DLL3 as a target.